Takeda bids adieu to Uloric
Takeda bids adieu to Uloric (febuxostat) after gout med's gradual fade from glory
The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. This week, the medicine, first approved in 2009, was listed as discontinued on the FDA’s online drug shortage database. The drug, also known as febuxostat, was cleared for chronic management of hyperuricemia—or high uric acid levels in the body—in patients with gout and was previously available in 40-mg and 80-mg tablets.
“As a global, R&D-driven biopharmaceutical company, we have taken this decision to help streamline our operational efficiencies and better dedicate our resources where they can provide the most value to patients,” a Takeda spokesperson told Fierce Pharma.
Since 2019, multiple generics referencing Uloric have hit the scene in the U.S., with just some 3% of patients using Takeda’s branded product versus generic competitors, the spokesperson added.
The move isn’t a total surprise, as the Japanese pharma told the FDA last year it planned to end production of branded Uloric at the end of 2024. To ease into the discontinuation, Takeda will continue to distribute Uloric to U.S. wholesalers through March 31, 2026, which should provide enough inventory for patients through the end of the year, the spokesperson said.
Uloric’s sales seem to have peaked in Takeda’s 2019 fiscal year, when the drug brought home 51.1 billion Japanese yen (then around $477 million). The following year, Takeda did not report directly on the drug’s sales, instead noting that revenue beyond its core therapeutic areas dropped 18.5%. The company blamed the issue, in part, on “off-patented products such as Uloric.”
Things started to take a turn for Uloric in 2017, when the FDA sent out a drug safety communication to the public signaling the medicine’s potential to cause increased cardiovascular events versus allopurinol—a widely available generic gout drug.
Subsequently, safety flags raised in a post-marketing study in 2018 prompted consumer advocacy group Public Citizen to petition the FDA to remove Uloric from the U.S. market.
Another blow struck in 2019, when the FDA revoked Uloric’s first-line treatment nod and added a boxed warning that the medication carried an increased risk of death compared to allopurinol.
